Oura patent suggests tracking AFib with signal quality testing

Oura received a patent describing a new method of detecting atrial fibrillation using a smart ring, which combines optical heart rate data with movement and temperature signals. The system focuses on using the AFib test only when conditions are stable, with the option to run an ECG reading for confirmation.

The filing, published earlier today, details how the ring can move beyond heart rate tracking and into something closer to clinical relevance. It does not depend on regular supervision. Instead, it introduces a more specialized approach designed to improve accuracy without draining battery or overloading users with alerts.

A smart way to decide when to weigh

One of the main concepts in copyright is time.

Wearables that monitor the eye in Afib can track continuously or periodically. That sounds logical, but it creates a problem. Most of the data collected during daily movement is noisy. Walking, typing or slight hand movements can distort optical signals.

Oura’s way is to wait.

The system checks if the user is fit and if the device has good contact with the skin. It uses motion sensors and temperature readings to make that call. Only if those signals suggest stable conditions do they use AFib analysis.

Two-stage detection is built around PPG and ECG

The patent also describes the process of obtaining the layers.

The first stage relies on PPG, the same optical system already used in many rings and watches. This allows the device to passively monitor the heart rhythm and flag potential abnormalities.

If something doesn’t work, the system can grow. It may prompt the user to read the ECG, assuming a future version of their ring supports it. That second step serves as a layer of validation rather than something that works all the time.

Cleaning the signal before making a call

Another part of the fulfillment focuses on how the data itself is handled.

The system creates a sequence of intervals between heartbeats and filters out irregular or noisy segments before starting the segmentation. This is important because the detection of AFib relies heavily on pattern recognition, not just raw heart rate.

Variable parameters and phase-based analysis are also discussed. That suggests the system can adjust how it interprets signals depending on the situation, rather than relying on fixed thresholds.

In simple words, it’s not just about looking for unusual beats. Trying to figure out if that abnormality is indicative of AFib.

Where Oura stands today

Currently, Oura does not offer AFib detection as a feature. Its ring focuses on heart rate, heart rate variability and sleep metrics. These can sometimes highlight abnormal patterns, but are not designed to diagnose an arrhythmia.

Some smart ring makers have already started going this route. Ultrahuman and Circular both offer types of AFib detection, indicating that the category is starting to expand beyond traditional health tracking.

This patent suggests that Oura is working on its own answer, but from a slightly different angle. Instead of forcing frequent detection, it tries to improve reliability by being more selective about when measurements occur.

Of course, patents don’t guarantee products, but this one sounds like a real problem.

This article first appeared on Gadgets & Wearables, the first media outlet to report the story.

Source: US Patent Office

Sign up for our monthly newsletter! Check out our YouTube channel.

And of course, you can follow Gadgets & Wearables on Google News and add us as a favorite source to get our expert news, reviews, and opinions in your feed.

The post Oura’s proprietary ideas for tracking AFib with signal quality testing appeared first on Gadgets & Wearables.